These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 7259326)

  • 1. Prostaglandin E1 infusions for vascular insufficiency in progressive systemic sclerosis.
    Martin MF; Dowd PM; Ring EF; Cooke ED; Dieppe PA; Kirby JD
    Ann Rheum Dis; 1981 Aug; 40(4):350-4. PubMed ID: 7259326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of refractory ischemic skin ulcers in patients with Raynaud's phenomenon with PGE1 infusions.
    Langevitz P; Buskila D; Lee P; Urowitz MB
    J Rheumatol; 1989 Nov; 16(11):1433-5. PubMed ID: 2600942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multiclinic, placebo-controlled, double-blind study of prostaglandin E1 in Raynaud's syndrome.
    Mohrland JS; Porter JM; Smith EA; Belch J; Simms MH
    Ann Rheum Dis; 1985 Nov; 44(11):754-60. PubMed ID: 3904643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis.
    Wigley FM; Seibold JR; Wise RA; McCloskey DA; Dole WP
    J Rheumatol; 1992 Sep; 19(9):1407-14. PubMed ID: 1279170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study.
    Rademaker M; Cooke ED; Almond NE; Beacham JA; Smith RE; Mant TG; Kirby JD
    BMJ; 1989 Mar; 298(6673):561-4. PubMed ID: 2467711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy evaluation of prostaglandin E1 against placebo in patients with progressive systemic sclerosis and significant Raynaud's phenomenon.
    Bartolone S; Trifiletti A; De Nuzzo G; Scamardi R; Larosa D; Sottilotta G; Raffa A; Barbera N
    Minerva Cardioangiol; 1999 May; 47(5):137-43. PubMed ID: 10479851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of vasospastic disease with prostaglandin E1.
    Clifford PC; Martin MF; Sheddon EJ; Kirby JD; Baird RN; Dieppe PA
    Br Med J; 1980 Oct; 281(6247):1031-4. PubMed ID: 7427564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostaglandin E1 vasospastic disease and thermography.
    Kyle V; Parr G; Salisbury R; Thomas PP; Hazleman B
    Ann Rheum Dis; 1985 Feb; 44(2):73-8. PubMed ID: 3977414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A double blind, randomised, multicentre comparison of two doses of intravenous iloprost in the treatment of Raynaud's phenomenon secondary to connective tissue diseases.
    Torley HI; Madhok R; Capell HA; Brouwer RM; Maddison PJ; Black CM; Englert H; Dormandy JA; Watson HR
    Ann Rheum Dis; 1991 Nov; 50(11):800-4. PubMed ID: 1722967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Botulinum toxin type A contribution in the treatment of Raynaud's phenomenon due to systemic sclerosis].
    Serri J; Legré R; Veit V; Guardia C; Gay AM
    Ann Chir Plast Esthet; 2013 Dec; 58(6):658-62. PubMed ID: 22204894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostaglandin E1 in severe Raynaud's phenomenon.
    Pardy BJ; Hoare MC; Eastcott HH; Miles CC; Needham TN; Harbourne T; Ellis BW
    Surgery; 1982 Dec; 92(6):953-65. PubMed ID: 6890719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of clonazepam on Raynaud's phenomenon and fingertip ulcers in scleroderma.
    Colakoğlu M; Cobankara V; Akpolat T
    Ann Pharmacother; 2007 Sep; 41(9):1544-7. PubMed ID: 17666574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low molecular weight dextran infusions in systemic sclerosis with Raynaud's phenomenon: a report of nine cases.
    Lane P
    Br Med J; 1970 Dec; 4(5736):657-9. PubMed ID: 5488384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of prostaglandin E1 on microvascular haemodynamics in progressive systemic sclerosis.
    Martin MF; Tooke JE
    Br Med J (Clin Res Ed); 1982 Dec; 285(6356):1688-90. PubMed ID: 6816332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of severe Raynaud's phenomenon with prostaglandin E1.
    Allen JA; O'Reilly MJ
    Ir J Med Sci; 1981 Jun; 150(6):190-1. PubMed ID: 7275566
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of topical rosemary essential oil on Raynaud phenomenon in systemic sclerosis.
    von Schoen-Angerer T; Deckers B; Henes J; Helmert E; Vagedes J
    Complement Ther Med; 2018 Oct; 40():191-194. PubMed ID: 30219447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Calcitonin gene-related peptide in treatment of severe peripheral vascular insufficiency in Raynaud's phenomenon.
    Bunker CB; Reavley C; O'Shaughnessy DJ; Dowd PM
    Lancet; 1993 Jul; 342(8863):80-3. PubMed ID: 8100913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effects of long-term iloprost therapy on Raynaud's phenomenon in progressive systemic sclerosis].
    Cordioli E; Virgilio S; Ghirardi R; Martinelli M
    Minerva Med; 1992 Nov; 83(11):739-44. PubMed ID: 1281297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of Raynaud's phenomenon in scleroderma with a new stable prostacyclin derivative].
    Keller J; Kaltenecker A; Schricker KT; Krais T; Schönberger A; Gevatter M; Hornstein OP
    Dtsch Med Wochenschr; 1984 Sep; 109(38):1433-8. PubMed ID: 6383760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The thermoregulatory effectiveness of calcitonin in progressive scleroderma].
    Gevatter M; Keller J; Hornstein OP
    Z Hautkr; 1989 Jun; 64(6):507-10. PubMed ID: 2669402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.